Innovation Delivered: Resco Launches Autumn Update at resco.next 2019 Keynote
24.10.2019 17:47:00 EEST | Business Wire | Press release
Resco, the leading provider of enterprise mobility solutions for Microsoft Dynamics 365 and Salesforce, has today officially introduced the Autumn Update 2019 at its annual resco.next conference in Rome.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191024005635/en/
Innovation delivered - Resco (Photo: Business Wire)
The release stands among Resco’s most significant, as it marks a year since the company officially began the expansion of its product portfolio with Resco Inspections, followed by Resco Routes. It delivers major new capabilities to both, as well as to the company’s Mobile Business Apps Platform.
“Our Autumn Update further strengthens Resco’s commitment to innovation that fosters business productivity. It also brings a number of features that extend Resco products to smartwatches,” confirmed Miro Pomsar, CEO at Resco.
More details in a fraction of time
With new Resco Inspections features like Tagged image and Reusable answers, field teams can complete inspections faster and provide more details with context to the back office. Ultimately, helping to speed up any issue resolution and boosting client satisfaction and loyalty.
Importantly, the solution is also coming to smartwatches as part of the Autumn Update. Field professionals can now complete inspection forms from their wrist, utilizing voice control for an entirely hands-free experience.
More information on Resco Inspections Autumn Update 2019 available here.
Handling unexpected situations
The upgraded Location Monitor in Resco Routes enables users to take the guesswork out of planning and effectively manage unforeseen events. Details such as an unlimited number of tracked staff members, real-time travel direction & speed, time of the last stop, and progress through the day, provide the backbone for truly informed decisions.
More information on Resco Routes Autumn Update 2019 available here.
Let the AI do the work
Resco’s Mobile Business Apps Platform has been extended with functionality that improves the efficiency of both mobile users and system administrators.
The all-new AI image recognition is available across all Resco-based app. Mobile users can now utilize image recognition instead of search or barcode scanning. More complex scenarios are also possible when utilizing image recognition in form rules.
Furthermore, when using Resco Cloud as a backend, administrators can create new fields and entities on the system directly from Woodford – no need to switch between applications. And with new project item categories, they can bring structure and clarity even to complex mobile projects.
More information on Resco’s Mobile Business Apps Platform Autumn Update 2019 available here.
Industry Watch for deeper business insights
At resco.next the company also introduced its all-new Industry Watch initiative - a new concept of utilizing smartwatches to obtain more insights from staff outdoors and indoors. Making entire organizations smarter and more efficient.
“We are excited about this new venture and the road that lies ahead. In the following months, we’re going to continue our intensive research in the area of wearables. We would also like to engage our whole ecosystem into this initiative, including our partners.” Miro Pomsar explained.
More details regarding Resco’s new smartwatch initiative can be found here.
About Resco
Resco founded in 1999, is one of the global leaders in developing cross-platform mobile software solutions. The team of Resco professionals utilizes their knowledge to design products for corporate customers, developers, integrators, and end users. Today, Resco is utilized by 2,800+ corporate customers with more than 250,000 licensed users around the world. The cornerstone of Resco’s Mobile Business Apps Platform is the Woodford configuration and management tool, which together with the Resco mobile app form the base of all Resco products.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191024005635/en/
Contact information
Resco Media Relations
Robert Feldmar
+421 2 209 020 17
communications@resco.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom